OIPE	
FEB 0 1 2007 &	
"Express Mail" meding Alabeth number _	EL 392680676US
Date of Deposit: 010102	

Our Case No. 10466/59

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)
Ashkenazi et al.	)
Serial No. 09/902,759	) Examiner To be assigned
Filing Date: July 10, 2001	) Group Art Unit No. 1645
For SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME	) )

## STATEMENT ACCORDING TO 37 C.F.R. § 1.821(f)

## **BOX SEQUENCE LISTING**

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Submitted herewith is a copy of the sequence listing in paper and computer readable form. Applicants' representative states that the content of the attached paper copy and compact disc copy in computer readable form of the Sequence Listing, submitted in accordance with 37 CFR 1.821(c) and (e), respectively, are identical.

Respectfully submitted,

Gregory M. Zinkl, Ph.D. Registration No. 48,492

Agent for Applicant

BRINKS HOFER GILSON & LIONE P.O. BOX 10395 CHICAGO, ILLINOIS 60610 (312) 321-4200

503CC TRANSMITTAL LETTER Case No. 10460/59 Serial No. RADEMARY Filing Date Examiner Group Art Unit 09/902,759 July 10, 2001 To be assigned 1645 Inventor(s) Ashkenazi et al. Title of Invention SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME TO THE COMMISSIONER FOR PATENTS Transmitted herewith is a Statement According to 37C.F.R. § 1.821(f); paper copy of Sequence Listing; copy of Sequence Listing in computer readable form; copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures and return postcard. Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted. A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed. Petition for a \_\_\_\_\_month extension of time. No additional fee is required. The fee has been calculated as shown below: Other Than Small Entity Small Entity Claims Highest No. or Remaining Previously Present I'bbA Add'I After Paid For Extra Rate Fee Rate Fee Amendment Total Minus x \$9= x \$18= Indep. Minus x 42 =x \$84= First Presentation of Multiple Dep. Claim +\$140= + \$280= Total Total add'I fee add'i fee Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$\_\_\_\_\_. A duplicate copy of this sheet is enclosed. A check in the amount of \$\_\_\_\_ to cover the filing fee is enclosed. The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed. M I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed. Respectfully submitted, Gregory M. Zinkl, Ph.D. Registration No. 48,492 Agent for Applicant **BRINKS HOFER GILSON & LIONE** P.O. BOX 10395 CHICAGO, ILLINOIS 60610 (312) 321-4200 I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail, label no. EL 392680676US, with sufficient postage, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on 0.2101.000

02-04-02

rev. Dec.-00

Date: \_ 02/c1/02



tent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/902,759

07/10/2001

Avi Ashkenazi

P1618P2C22

**CONFIRMATION NO. 9581** 

Date Mailed: 12/03/2001

**FORMALITIES LETTER** 

OC000000007147062\*

Paul E. Rauch, Ph.D. Brinks, Hofer, Gilson & Lione NBC Tower - Suite 3600 455 Cityfront Plaza Drive Chicago, IL 60611-5599



NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

 A request to transfer the computer readable form from another application on file at the U.S. Patent and Trademark Office has been submitted as permitted by 37 C.F.R. 1.821(e). However, the request cannot be complied with since there is no compliant CRF present at the United States Patent and Trademark Office. Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY